NCT03094286 - Durvalumab in HIV-1 Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

April 24, 2019

Study Completion Date

March 22, 2022

Conditions

HIVCancer

Interventions

DRUG

Durvalumab

Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled

Trial Locations (8)

28222

Hospital Puerta de Hierro, Madrid

41013

Hospital Virgen del Rocío, Seville

08916

ICO-Badalona, Badalona

08220

Consorci Sanitari de Terrassa, Terrassa

08036

H. Clínic i Provincial de Barcelona, Barcelona

H. Universitario Quirón Dexeus, Barcelona

Unknown

H. La Paz, Madrid

Hospital La Fe, Valencia

All Listed Sponsors

lead

Spanish Lung Cancer Group

OTHER